Can Exosomes Help With Back Pain & Disc Degeneration? What the Research Says

Low back pain can have many different causes.

Muscles, ligaments, nerves, facet joints and the intervertebral discs can all contribute to pain in different people.

One area attracting growing interest in extracellular-vesicle research is intervertebral disc degeneration — the progressive biological and structural deterioration of the discs that sit between the vertebrae of the spine.

Researchers are investigating whether extracellular vesicles, including exosomes, may influence some of the processes associated with disc degeneration, including inflammation, cell survival, extracellular-matrix breakdown and the biological activity of nucleus pulposus cells inside the disc.

The research has progressed from laboratory experiments into numerous animal studies, and a small amount of human clinical research involving low-back pain has also been published.

The evidence is encouraging — but the distinction between back pain, facet-joint pain and disc degeneration is important.

So what exactly are researchers finding?

What Does the Research Show?

Research involving extracellular vesicles and the spine currently spans several different levels.

Laboratory studies have investigated how EVs interact with human degenerative disc cells and the molecular pathways involved in disc degeneration.

Animal studies have examined whether EV preparations can influence disc structure, disc height, extracellular matrix, inflammation and cell survival after experimentally induced disc degeneration.

A 2024 systematic review and meta-analysis identified 13 articles comprising 19 studies and 218 experimental animals investigating cell-derived extracellular vesicles for intervertebral disc degeneration.

Compared with placebo, the pooled research reported:

• lower MRI degeneration grades
• greater disc-height index
• reduced nucleus-pulposus-cell apoptosis
• improved histological grading

The authors concluded that the accumulated preclinical evidence supported continued investigation of EVs as a potential approach to intervertebral disc degeneration.

Human research is much smaller.

A separate 2024 review specifically searched for clinical studies using extracellular vesicles or exosomes for low-back pain. Only two published articles met its inclusion criteria through March 18, 2024. The reviewers characterized the early clinical findings as potentially encouraging while emphasizing the need for larger, adequately powered, multicenter studies with longer follow-up.

That difference matters.

There is a growing preclinical evidence base for disc biology, but considerably less clinical evidence showing what happens when EV preparations are used in people with back pain.

What Is Intervertebral Disc Degeneration?

The spine contains a series of intervertebral discs positioned between the vertebrae.

Each disc has different structural regions.

At the center is the nucleus pulposus, a hydrated, gel-like tissue that helps distribute mechanical loads.

Surrounding it is the annulus fibrosus, a tougher fibrous structure that helps contain the nucleus and stabilize the disc.

Healthy discs depend on a carefully maintained extracellular matrix rich in molecules that help the tissue retain water and withstand compression.

As discs degenerate, that biological environment changes.

Researchers studying intervertebral disc degeneration have focused on processes including:

• loss or dysfunction of disc cells
• extracellular-matrix degradation
• inflammatory signaling
• cellular senescence
• apoptosis
• reduced tissue hydration
• structural deterioration

A 2025 review of EV research for intervertebral disc degeneration describes extracellular vesicles as being investigated for their potential influence on cell loss and senescence, extracellular-matrix degeneration and the inflammatory microenvironment.

That's why EVs have become interesting in disc research.

Researchers aren't simply asking whether they can temporarily change someone's perception of pain.

They're asking whether extracellular-vesicle signaling can influence the biology of the degenerating disc itself.

Research Highlight: EVs and Human Degenerative Disc Cells

One particularly useful laboratory study used disc cells obtained from people with degenerative discs and chronic low-back pain.

Researchers isolated small extracellular vesicles from human bone-marrow mesenchymal stem cells and exposed degenerative human disc cells to them in a three-dimensional culture system.

The EV concentration was reported as 5 × 10¹⁰ vesicles/mL, and the cells were studied for 28 days.

Researchers evaluated:

• cell proliferation
• cell viability
• extracellular-matrix production
• apoptosis
• chondrogenic activity
• cytokine secretion

What happened?

The researchers reported more than a 50% increase in cell proliferation along with decreased apoptosis.

Extracellular-matrix production was observed as early as day seven and was reported to be more than three times higher in EV-treated disc-cell pellets compared with control cultures.

The EV-treated cells also showed reduced secretion of MMP-1, an enzyme involved in extracellular-matrix breakdown.

Why is this study interesting?

Unlike an experiment performed entirely using rodent cells, the disc cells in this experiment came from human patients with degenerative discs and chronic low-back pain.

That makes the biological model particularly relevant.

What is the important limitation?

These were human cells in a laboratory — not people receiving an EV treatment.

A favorable response in cultured human disc cells does not establish that injecting an EV preparation into a person's spine would produce the same response.

It tells researchers that human degenerative disc cells can respond to this particular EV preparation under controlled laboratory conditions.

That's an important step, but it remains preclinical evidence.

What Does the Larger Animal Evidence Show?

Individual laboratory experiments become more useful when they fit into a larger pattern.

That's where the 2024 meta-analysis by Li and colleagues becomes important.

The researchers systematically searched PubMed, Embase and the Cochrane Library for studies evaluating cell-derived extracellular vesicles in intervertebral disc degeneration.

They ultimately analyzed 13 articles comprising 19 studies and 218 experimental animals.

The researchers examined several outcomes commonly used to evaluate disc degeneration.

MRI degeneration

MRI can reveal changes associated with disc degeneration.

The pooled analysis found significantly lower MRI Pfirrmann degeneration grades in EV-treated animals compared with placebo groups.

Disc height

Degenerating discs can lose height as their structure changes.

EV-treated animals showed greater disc-height index values compared with placebo groups in the pooled analysis.

Histology

Researchers can also examine disc tissue microscopically to evaluate structural degeneration.

Histological grading was improved in the EV groups.

Cell survival

The analysis also found reduced apoptosis among nucleus pulposus cells.

Taken together, these findings suggest that EV treatment influenced several different aspects of experimentally induced disc degeneration — not simply one isolated laboratory measurement.

But there is a major limitation:

These were animal experiments.

They provide evidence about biological plausibility and help researchers determine what should be tested next. They do not establish that the same structural changes occur in human discs.

Research Highlight: Engineered EVs and Discogenic Back Pain

A 2024 study took the research in another interesting direction.

Instead of using ordinary extracellular vesicles alone, researchers engineered EVs to deliver FOXF1, a developmental transcription factor, into degenerated intervertebral discs.

The goal was essentially to use extracellular vesicles as biological delivery vehicles.

Researchers evaluated the approach in an animal model of discogenic back pain.

The study reported reductions in pain-related behaviors, although the response showed sex-specific differences.

Researchers also reported changes involving:

• disc height
• tissue hydration
• proteoglycan content
• mechanical properties

The authors described significant restoration of disc structure and function in animals receiving FOXF1-loaded engineered EVs.

This experiment is particularly interesting because it connects two research goals that are often considered separately: what happens to the structure of the disc, and what happens to pain-related behavior.

What is the important limitation?

This was an engineered gene-delivery system in an animal model.

The extracellular vesicles were specifically loaded with FOXF1.

That is fundamentally different from an ordinary naturally derived EV preparation.

The results therefore shouldn't be generalized to other extracellular-vesicle products simply because they also contain EVs.

And animal pain behaviors are not equivalent to a person reporting relief from chronic back pain.

Still, the study demonstrates how researchers are beginning to explore extracellular vesicles not only as biological signals themselves, but also as delivery platforms for targeted molecular cargo.

What About Actual People With Back Pain?

This is where we need to separate the promising experimental evidence from the much smaller human literature.

A 2024 review specifically examining clinical EV/exosome research for low-back pain found only two published clinical articles meeting its criteria.

One of those studies provides an interesting early human example: a three-month pilot study involving 20 adults with lumbar facet-joint pain, summarized in the Research Highlight below.

Participants received an investigational extracellular-vesicle product derived from bone-marrow mesenchymal stem cells, injected into the lumbar facet-joint space at 0.5 mL per joint, with evaluations on days 1, 3, 7, 14, 30, 60 and 90.

No adverse effects or complications were reported during the three-month follow-up, and there were no reports of worsening pain.

At three months, group-average scores reportedly improved by 65.04% on the Severity Index, 72.09% on the Interference Index and 58.43% on the Oswestry Disability Index. The reported changes were statistically significant (p < 0.0001).

Those are encouraging early findings.

But this study requires careful interpretation.

This was facet-joint pain — not a disc-regeneration study

The investigators injected the preparation into lumbar facet joints.

They did not inject degenerating intervertebral discs and demonstrate that those discs regenerated.

Facet joints and intervertebral discs are different anatomical structures and can represent different sources of back pain.

We shouldn't combine those findings simply because both conditions can hurt in the lower back.

There was no placebo/control group

All 20 participants received the investigational product.

Without a randomized control group, the study cannot determine how much of the observed improvement resulted specifically from the EV preparation rather than other influences.

The authors themselves called for randomized controlled clinical studies to confirm the potential benefits.

There was industry involvement

The investigational product, ExoFlo, was provided by Direct Biologics.

The published disclosure states that one author reported minority ownership in Direct Biologics, another was the company's chief medical officer, and another was a senior company employee.

That doesn't invalidate the findings.

It is simply important context when evaluating a small uncontrolled pilot study.

Back Pain Is Not One Disease

This may be the most important consumer takeaway from the entire article.

Someone saying “my back hurts” doesn't tell us what's causing the pain.

Potential sources can include:

• intervertebral discs
• facet joints
• muscles and connective tissues
• nerve irritation
• spinal stenosis
• vertebral structures
• sacroiliac structures
• combinations of several problems

Even within disc-related conditions, structural degeneration visible on imaging and a person's symptoms don't always tell exactly the same story.

So when reading an exosome study, the first question should be: what condition did the researchers actually study?

A study of lumbar facet-joint pain cannot automatically answer whether EVs influence disc degeneration.

An animal experiment involving a punctured intervertebral disc cannot establish what happens in a person with chronic facet-joint pain.

And an experiment involving cultured human disc cells cannot tell us how much pain a person would experience.

Those distinctions make the research more — not less — useful because they tell us precisely what each experiment contributes. The same interpretation questions come up in other joint and tendon research, such as what the research says about knee pain and rotator cuff and tendon injuries.

What About Exosome-Loaded Hydrogels?

Another rapidly developing area involves combining extracellular vesicles with hydrogels.

One challenge researchers face when studying EV delivery inside a damaged tissue is keeping the preparation where they want it for an appropriate period.

Hydrogels can act as biomaterial carriers designed to retain and release EVs locally.

A 2025 systematic review and meta-analysis specifically examined exosome-loaded hydrogels in preclinical animal models of intervertebral disc degeneration.

This represents a broader trend we've seen in several areas of EV research.

Scientists aren't investigating only which EVs should be used. They're also investigating how those EVs should be delivered.

That distinction matters because an EV preparation incorporated into an engineered hydrogel is not equivalent to the same particles delivered in a simple solution.

Formulation can be part of the experimental intervention.

Why EV Source and Preparation Matter

The spine literature reinforces something we've seen repeatedly throughout extracellular-vesicle research: not all EV preparations are interchangeable. If you are comparing commercially available products, see how to evaluate an exosome product.

The studies discussed in this article include very different experimental materials.

The human disc-cell experiment used small EVs derived from cultured human bone-marrow mesenchymal stem cells.

The facet-joint pilot used a bone-marrow-MSC-derived extracellular-vesicle investigational product.

The FOXF1 experiment used engineered extracellular vesicles carrying a specific transcription factor.

Other disc-degeneration studies have used different cellular sources, EV modifications and delivery systems. For background on how source material differs, see where exosomes come from.

Preparations can differ in:

• biological source
• culture conditions
• cell passage
• isolation
• purification
• particle concentration
• characterization
• molecular cargo
• formulation
• delivery route
• administration schedule

A 2025 review of extracellular-vesicle research for intervertebral disc degeneration describes ongoing engineering work aimed at improving targeting and therapeutic efficacy, and the 2025 hydrogel meta-analysis concluded that further investigation of mechanisms, safety and efficacy is required before clinical application. How a preparation is measured and documented is itself a variable — see extracellular vesicle characterization and testing.

Seeing the word “exosome” in two papers therefore does not mean the researchers tested equivalent biological materials.

Why Results May Vary

As with many biologically active interventions, people may not respond identically. Individual genetics, age, underlying biology, disease severity and other person-specific factors may influence biological responses. The extracellular-vesicle preparation itself—including its source, manufacturing, characterization and formulation—may also matter. Researchers are still working to understand which factors may help predict how individuals respond.

For back pain, there's another major source of variability: the underlying cause of the pain itself.

Two people can both describe chronic lower-back pain while having very different underlying anatomy and biology.

That means future research will need to do more than determine whether an EV intervention produces an average effect.

Researchers will also need to determine which types of back pain and which patient characteristics are most appropriate to study.

The Bottom Line

Extracellular-vesicle research involving intervertebral disc degeneration has developed into a meaningful preclinical field.

A 2024 meta-analysis encompassing 19 studies and 218 experimental animals reported favorable findings involving MRI degeneration grade, disc-height index, histological grading and nucleus-pulposus-cell apoptosis.

Laboratory experiments using degenerative disc cells obtained from human patients have also reported changes involving cell proliferation, apoptosis and extracellular-matrix production after exposure to MSC-derived small extracellular vesicles.

More advanced animal experiments are now exploring engineered EVs capable of delivering specific molecular cargo while researchers investigate both disc structure and pain-related behavior.

Human evidence is beginning to appear, but it remains limited.

A 20-person pilot study of bone-marrow-MSC-derived EVs for lumbar facet-joint pain reported significant improvements in several pain/function measures over three months, but the study was uncontrolled, small, industry-associated and did not investigate intervertebral-disc regeneration.

A 2024 clinical review found only two qualifying published human studies and concluded that larger, adequately powered, multicenter studies with longer follow-up are needed.

So the current picture is encouraging but still developing: the biological and preclinical evidence for EVs in disc degeneration is considerably further along than the human clinical evidence.